Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.
October 9, 2003 Comments Off on Stem cell bill eyed as lure to biotech firms Posted in: General Biotechnology Stem cell bill eyed as lure to biotech firms A redraft may be in its future, but supporters of a proposed Bay State bill filed last winter that would formally welcome and set boundaries for stem cell research here say the measure will be an important part of the legislative agenda in the coming months.